e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm
Thierry Berghmans, Anne-Marie Dingemans, Lizza E.L. Hendriks, Jacques Cadranel
Source:
Eur Respir J, 55 (2) 1901907; 10.1183/13993003.01907-2019
Journal Issue:
February
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Thierry Berghmans, Anne-Marie Dingemans, Lizza E.L. Hendriks, Jacques Cadranel. Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm. Eur Respir J, 55 (2) 1901907; 10.1183/13993003.01907-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Challenges in the management of SCLC
Related content which might interest you:
Therapeutic options targeting angiogenesis in nonsmall cell lung cancer
Source: Eur Respir Rev 2014; 23: 79-91
Year: 2014
Biological therapies in nonsmall cell lung cancer
Source: Eur Respir J , 49 (3) 1601520; DOI: 10.1183/13993003.01520-2016
Year: 2017
Targeted therapy in non-small cell lung cancer
Source: Breathe 2012; 8: 206-215
Year: 2012
Anticancer treatment for advanced non-small cell lung cancer
Source: Breathe 2011; 8: 124-133
Year: 2011
New treatment options for nonsmall cell lung cancer and small cell lung cancer
Source: Annual Congress 2006 - PG12 - Small cell lung cancer management
Year: 2006
Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives
Source: Eur Respir Rev 2011; 20: 45-52
Year: 2011
Update on nonsmall cell lung cancer
Source: Eur Respir Rev 2010 19: 173-185
Year: 2010
The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Second line therapy for advanced non-small cell lung cancer
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Radiotherapy in the treatment of nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 207–243
Year: 2009
New chemotherapeutic agents
Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=259
Year: 2001
Response to Immunotherapy in non-small cell lung cancer: the effect of weight
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
Utilisation of biomarker testing to guide therapy in non-small cell lung cancer in a regional lung cancer service
Source: International Congress 2018 – Genetics in chronic pulmonary diseases
Year: 2018
Does the incorporation of new generation cytotoxic agent improve the overall outcome in inoperable nonsmall cell lung cancer (NSCLC)?
Source: Eur Respir J 2003; 22: Suppl. 45, 64s
Year: 2003
Radio(chemo)therapy in locally advanced nonsmall cell lung cancer
Source: Eur Respir Rev 2015; 25: 65-70
Year: 2016
Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies
Source: International Congress 2019 – State of the art session: Thoracic oncology
Year: 2019
The treatment of stage IV non-small cell lung cancer with target therapies
Source: Annual Congress 2013 –Which treatment other than chemotherapy for stage IV NSCLC?
Year: 2013
Our experience with crizotinib in the treatment of non-small cell lung cancer
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept